Please assess the completion status of the following clinical trial:

Trial Title: Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients shall have normal organic function such as liver function, Cardiac function and renal function;~2. male or female age \>18 years old;~3. diagnosis GI cancer with histology;~4. Chronic neurotoxicity grade is 2 or more~5. Karnofsky Performance scores should be 80 or more~6. patients are in oxaliplatin-based chemotherapy courses or no more than 21 days after last oxaliplatin usage for patients who will discontinue oxaliplatin usage.~7. without uncured tumor except GI cancer,~8. Patients should be expected to live no shorter than 3 months~Exclusion Criteria:~1. patients who is receiving anti-neurotoxicity treatment;~2. WBC\<4.0×109/L，ANC\<1.5×109/L,PLT\<100×109/L，Hb\<90g/L,TBIL\>1.5Limitation;BUN）\>1.5Limitation；Cr）\>1.5Limitation；ALT or AST\>2.5Limitation（without liver metastasis）；ALT or AST）\>5Limitation（with liver metastasis）;~3. heart dysfunction;~4. brain metastasis with symptoms;~5. peripheral nervous system or central nervous system abnormal including diabetes mellitus patients with neuropathy;~6. in situation of oxaliplatin-based chemotherapy progressed, the next chemotherapy regime should not contain agents which will cause neurotoxicity (such as paclitaxel and cisplatin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo+oxaliplatin-based chemotherapy (Type: PLACEBO_COMPARATOR): equal saline as placebo, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
- GM+oxaliplatin-based chemotherapy (Type: EXPERIMENTAL): monosialotetrahexosylganglioside Sodium Injection, 40mg or 60mg, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.

Based on this trial design, predict the completion outcome and termination type (if applicable).